ALPMY - Arvinas Holding Prepares Terms For $100 Million IPO
Quick Take
Arvinas Holding (ARVN) intends to raise $100 million from the sale of its common stock in a U.S. IPO, per an amended registration statement.
The company is advancing a pipeline of drug candidates for the treatment of various cancers.
ARVN has enviable licensing partnerships, a large amount of liquid resources, and shareholder support for the IPO.
Company & Technology
New Haven, Connecticut-based Arvinas was founded in 2013 to discover and commercialize therapies that degrade disease-causing proteins for the treatment of patients with debilitating or life-threatening diseases such as prostate and